When biopharmaceutical company Invex Therapeutics (“Invex”) first decided to launch a clinical trial to evaluate Presendin (sustained-release exenatide) for idiopathic intracranial hypertension (IIH), the company felt excited. Presendin is a…
Some conditions or diseases are more prevalent in certain groups. In the case of idiopathic intracranial hypertension (IIH), new research suggests that it is much more common in Black or…
Typically, idiopathic intracranial hypertension (IIH) is associated with obesity, or a body mass index (BMI) over 30.0. As obesity rates have continued to increase globally, so have the incidences of…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
As shared in a press release by the American Academy of Neurology; the medical community had taken note of the rare brain pressure disorder idiopathic intracranial hypertension (IIH) when they…
Written by Jennifer Peterson As a young adult, this journey was not something I ever imagined taking, and it certainly was not for the faint of heart. Being diagnosed with…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
